Nyxoah (NASDAQ:NYXH – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.
Institutional & Insider Ownership
1.3% of InspireMD shares are held by institutional investors. 21.6% of InspireMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Nyxoah has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, InspireMD has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $3.25 million | N/A | -$32.90 million | ($1.74) | -4.75 |
| InspireMD | $5.17 million | 14.55 | -$18.49 million | ($1.95) | -1.82 |
InspireMD has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nyxoah and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,457.29% | -35.76% | -29.27% |
| InspireMD | -349.99% | -75.20% | -59.26% |
Analyst Ratings
This is a breakdown of current recommendations for Nyxoah and InspireMD, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 0 | 1 | 4 | 0 | 2.80 |
| InspireMD | 0 | 0 | 1 | 0 | 3.00 |
Nyxoah currently has a consensus target price of $13.00, indicating a potential upside of 66.25%. InspireMD has a consensus target price of $5.20, indicating a potential upside of 46.48%. Given Nyxoah’s higher probable upside, research analysts clearly believe Nyxoah is more favorable than InspireMD.
Summary
InspireMD beats Nyxoah on 7 of the 13 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
